{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:25:07Z","timestamp":1790601907727,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ethiopian Public Health Institute"},{"DOI":"10.13039\/501100007941","name":"Addis Ababa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In 2004, Ethiopia adopted artemether-lumefantrine (AL, Coartem<jats:sup>\u00ae<\/jats:sup>) as first-line treatment for the management of uncomplicated <jats:italic>Plasmodium falciparum<\/jats:italic> malaria. Continuous monitoring of AL therapeutic efficacy is crucial in Ethiopia, as per the World Health Organization (WHO) recommendation. This study aimed to assess the therapeutic efficacy of AL in the treatment of uncomplicated <jats:italic>P. falciparum<\/jats:italic> infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A 28\u00a0day onearm, prospective evaluation of the clinical and parasitological response to AL was conducted at Shecha Health Centre, Arba Minch town, Southern Ethiopia. Patients were treated with six-dose regimen of AL over three days and monitored for 28 days with clinical and laboratory assessments. Participant recruitment and outcome classification was done in accordance with the 2009 WHO methods for surveillance of anti-malarial drug efficacy guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 88 study participants were enrolled and 69 of them completed the study with adequate clinical and parasitological response. Two late parasitological failures were observed, of which one was classified as a recrudescence by polymerase chain reaction (PCR). The PCRcorrected cure rate was 98.6% (95% CI 92.3\u2013100). AL demonstrated a rapid parasite and fever clearance with no parasitaemia on day 2 and febrile cases on day 3. Gametocyte clearance was complete by day three. No serious adverse events were reported during the 28 days follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study demonstrated high therapeutic efficacy and good safety profile of AL. This suggests the continuation of AL as the first-line drug for the treatment of uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria in Ethiopia. Periodic therapeutic efficacy studies and monitoring of markers of resistance are recommended for early detection of resistant parasites.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04436-8","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T09:06:49Z","timestamp":1673082409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch, Ethiopia"],"prefix":"10.1186","volume":"22","author":[{"given":"Kale","family":"Gubae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heven","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henok","family":"Hailgiorgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anteneh Kassahun","family":"Mare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokretsion","family":"Gidey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mebrahtom","family":"Haile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudissa","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worku","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geremew","family":"Tasew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon Mequanente","family":"Abay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"key":"4436_CR1","unstructured":"WHO. Guidelines for malaria \u2013 2021. Geneva, World Health Organization; 2021."},{"key":"4436_CR2","unstructured":"WHO. Tackling antimalarial drug resistance - key definitions. Geneva. World Health Organization; 2019."},{"key":"4436_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1051\/parasite\/2018021","volume":"25","author":"M Ouji","year":"2018","unstructured":"Ouji M, Augereau JM, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of damocles in the path toward malaria elimination. Parasite. 2018;25:24.","journal-title":"Parasite"},{"key":"4436_CR4","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response. Geneva, World Health Organization; 2019."},{"key":"4436_CR5","volume-title":"Diagnosis and treatment guidelines for health workers in Ethiopia","author":"Federal Democratic Republic of Ethiopia Ministry of Health","year":"2004","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. Diagnosis and treatment guidelines for health workers in Ethiopia. 2nd ed. Ethiopia: Addis Abbaba; 2004.","edition":"2"},{"key":"4436_CR6","first-page":"387","volume":"82","author":"D Jima","year":"2005","unstructured":"Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O. Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J. 2005;82:387\u201390.","journal-title":"East Afr Med J"},{"key":"4436_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12936-020-03307-4","volume":"19","author":"A Abamecha","year":"2020","unstructured":"Abamecha A, Yilma D, Addisu W, Abid H, El, Ibenthal A, Noedl H, et al. Therapeutic efficacy of artemether \u2013 lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia. Malar J. 2020;19:240.","journal-title":"Malar J"},{"key":"4436_CR8","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"4436_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4314\/ejhs.v20i3.69448","volume":"20","author":"A Astatkie","year":"2011","unstructured":"Astatkie A. Knowledge and practice of malaria prevention methods among residents of Arba Minch Town and Arba Minch Zuria District, Southern Ethiopia. Ethiop J Health Sci. 2011;20:185\u201393.","journal-title":"Ethiop J Health Sci"},{"key":"4436_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1475-2875-11-240","volume":"11","author":"T Eshetu","year":"2012","unstructured":"Eshetu T, Abdo N, Bedru KH, Fekadu S, Wieser A, Pritsch M, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia. Malar J. 2012;11:240.","journal-title":"Malar J"},{"key":"4436_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1475-2875-10-209","volume":"10","author":"J Hwang","year":"2011","unstructured":"Hwang J, Alemayehu BH, Hoos D, Melaku Z, Tekleyohannes SG, Teshi T, et al. In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in central Ethiopia. Malar J. 2011;10:209.","journal-title":"Malar J"},{"key":"4436_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-015-0775-3","volume":"14","author":"G Getnet","year":"2015","unstructured":"Getnet G, Fola AA, Alemu A, Getie S, Fuehrer HP, Noedl H. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar J. 2015;14:258.","journal-title":"Malar J"},{"key":"4436_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12936-015-0826-9","volume":"14","author":"SK Mekonnen","year":"2015","unstructured":"Mekonnen SK, Medhin G, Berhe N, Clouse RM, Aseffa A. Efficacy of artemether-lumefantrine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Southwestern Ethiopia. Malar J. 2015;14:317.","journal-title":"Malar J"},{"key":"4436_CR14","doi-asserted-by":"publisher","first-page":"e0154618","DOI":"10.1371\/journal.pone.0154618","volume":"11","author":"D Nega","year":"2016","unstructured":"Nega D, Assefa A, Mohamed H, Solomon H, Woyessa A, Assefa Y, et al. Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) in treating uncomplicated P. falciparum malaria in Metehara, Eastern Ethiopia: regulatory clinical study. PLoS ONE. 2016;11:e0154618.","journal-title":"PLoS ONE"},{"key":"4436_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-3-1","volume":"3","author":"A Assefa","year":"2010","unstructured":"Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T. Therapeutic efficacy of Artemether\/Lumefantrine (Coartem \u00ae) against Plasmodium falciparum in Kersa, South West Ethiopia. Parasit Vectors. 2010;3:1.","journal-title":"Parasit Vectors"},{"key":"4436_CR16","doi-asserted-by":"publisher","first-page":"8907","DOI":"10.1038\/s41598-020-65553-5","volume":"10","author":"MA Diallo","year":"2020","unstructured":"Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diongue K, Sy SA, et al. Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and pfcoronin molecular markers in treatment failure in Senegal. Sci Rep. 2020;10:8907.","journal-title":"Sci Rep"},{"key":"4436_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J"},{"key":"4436_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18:231.","journal-title":"Malar J"},{"key":"4436_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12936-021-03745-8","volume":"20","author":"A Abamecha","year":"2021","unstructured":"Abamecha A, Yilma D, Adissu W, Yewhalaw D, Abdissa A. Efficacy and safety of artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. Malar J. 2021;20:213.","journal-title":"Malar J"},{"key":"4436_CR20","unstructured":"WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva, World Health Organization; 2019."},{"key":"4436_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4269\/ajtmh.2003.69.558","volume":"69","author":"AA Djimd\u00e9","year":"2003","unstructured":"Djimd\u00e9 AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69:558\u201363.","journal-title":"Am J Trop Med Hyg"},{"key":"4436_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4269\/ajtmh.2004.71.531","volume":"71","author":"G Dorsey","year":"2004","unstructured":"Dorsey G, Gasasira AF, Machekano R, Kamya MR, Staedke SG, Hubbard A. The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. Am J Trop Med Hyg. 2004;71:531\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"4436_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/500951","volume":"193","author":"D Francis","year":"2006","unstructured":"Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Machekano R, et al. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis. 2006;193:978\u201386.","journal-title":"J Infect Dis"},{"key":"4436_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1086\/596741","volume":"199","author":"B Greenhouse","year":"2009","unstructured":"Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Clark TD, et al. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis. 2009;199:758\u201365.","journal-title":"J Infect Dis"},{"key":"4436_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/CMR.00025-08","volume":"22","author":"DL Doolan","year":"2009","unstructured":"Doolan DL, Doba\u00f1o C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13\u201336.","journal-title":"Clin Microbiol Rev"},{"key":"4436_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.5897\/AJBx09.034","volume":"9","author":"RK Obi","year":"2010","unstructured":"Obi RK, Okangba CC, Nwanebu FC, Ndubuisi UU, Orji NM. Premunition in Plasmodium falciparum malaria. Afr J Biotechnol. 2010;9:1397\u2013401.","journal-title":"Afr J Biotechnol"},{"key":"4436_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WWARN Lumefantrine PK\/PD Study Group","year":"2015","unstructured":"WWARN Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13:227.","journal-title":"BMC Med"},{"key":"4436_CR28","first-page":"548710","volume":"2012","author":"G Kinfu","year":"2012","unstructured":"Kinfu G, Gebre-Selassie S, Fikrie N. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Northern Ethiopia. Malar Res Treat. 2012;2012:548710.","journal-title":"Malar Res Treat"},{"key":"4436_CR29","doi-asserted-by":"publisher","first-page":"e0176004","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE. 2017;12:e0176004.","journal-title":"PLoS ONE"},{"key":"4436_CR30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/TCRM.S113603","volume":"12","author":"F Wudneh","year":"2016","unstructured":"Wudneh F, Assefa A, Nega D, Mohammed H, Solomon H, Kebede T, et al. Open-label trial on efficacy of artemether\/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district, Northwestern Ethiopia. Ther Clin Risk Manag. 2016;12:1293\u2013300.","journal-title":"Ther Clin Risk Manag"},{"key":"4436_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.1155165","volume":"320","author":"NJ White","year":"2008","unstructured":"White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330\u20134.","journal-title":"Science"},{"key":"4436_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/TCRM.S127571","volume":"13","author":"T Deressa","year":"2017","unstructured":"Deressa T, Seid ME, Birhan W, Aleka Y, Tebeje BM. In vivo efficacy of artemether\u2013lumefantrine against uncomplicated Plasmodium falciparum malaria in dembia district, northwest Ethiopia. Ther Clin Risk Manag. 2017;13:201\u20136.","journal-title":"Ther Clin Risk Manag"},{"key":"4436_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-015-0744-x","volume":"14","author":"YA Ebstie","year":"2015","unstructured":"Ebstie YA, Zeynudin A, Belachew T, Desalegn Z, Suleman S. Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem\u00ae) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Malar J. 2015;14:236.","journal-title":"Malar J"},{"key":"4436_CR34","first-page":"42","volume":"6","author":"ZZ Kanche","year":"2016","unstructured":"Kanche ZZ, Woticha EW, Gidebo KD. Therapeutic efficacy and safety of artemether-lumefantrine (Coartem \u00ae) in therapeutic efficacy and safety of artemether-lumefantrine (Coartem \u00ae) in uncomplicated P. falciparum malaria in Wolaita. J Biol Agric Healthc. 2016;6:42\u20138.","journal-title":"J Biol Agric Healthc"},{"key":"4436_CR35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"4436_CR36","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3201\/eid2404.170141","volume":"24","author":"HS Rates","year":"2018","unstructured":"Rates HS, Yatsushiro S, Takahashi N, Yamauchi M, Sekihara M, Hashimoto M, et al. Artemisinin-resistant Plasmodium falciparum with high survival rates, Uganda, 2014\u20132016. Emerg Infect Dis. 2018;24:718\u201326.","journal-title":"Emerg Infect Dis"},{"key":"4436_CR37","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2021","unstructured":"Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J Infect Dis. 2021;225:1411\u20134.","journal-title":"J Infect Dis"},{"key":"4436_CR38","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4436_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1475-2875-9-136","volume":"9","author":"T Bousema","year":"2010","unstructured":"Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J. 2010;9:136.","journal-title":"Malar J"},{"key":"4436_CR40","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1086\/503051","volume":"193","author":"JT Bousema","year":"2006","unstructured":"Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151\u20139.","journal-title":"J Infect Dis"},{"key":"4436_CR41","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/319689","volume":"183","author":"G Targett","year":"2001","unstructured":"Targett G, Drakeley C, Jawara M, Von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183:1254\u20139.","journal-title":"J Infect Dis"},{"key":"4436_CR42","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1371\/journal.pmed.0020330","volume":"2","author":"KI Barnes","year":"2005","unstructured":"Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2005;2:e330.","journal-title":"PLoS Med"},{"issue":"Suppl 1","key":"4436_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1475-2875-8-S1-S8","volume":"8","author":"KI Barnes","year":"2009","unstructured":"Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether\/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J. 2009;8(Suppl 1):8.","journal-title":"Malar J"},{"key":"4436_CR44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40264-013-0044-8","volume":"36","author":"PU Bassi","year":"2013","unstructured":"Bassi PU, Osakwe AI, Isah A, Suku C, Kalat M, Jalo I, et al. Safety of artemisinin-based combination therapies in Nigeria: a cohort event monitoring study. Drug Saf. 2013;36:747\u201356.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"4436_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2875-8-S1-S6","volume":"8","author":"C Falade","year":"2009","unstructured":"Falade C, Manyando C. Safety profile of Coartem\u00ae: the evidence base. Malar J. 2009;8(Suppl 1):6.","journal-title":"Malar J"},{"key":"4436_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40261-016-0385-z","volume":"36","author":"AK Mssusa","year":"2016","unstructured":"Mssusa AK, Fimbo AM, Nkayamba AF, Irunde HF, Sillo HB, Shewiyo DH, et al. Safety profile of artemether-lumefantrine: a cohort event monitoring study in public health facilities in Tanzania. Clin Drug Investig. 2016;36:401\u201311.","journal-title":"Clin Drug Investig"},{"key":"4436_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12936-015-0649-8","volume":"14","author":"A Shayo","year":"2015","unstructured":"Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malar J. 2015;14:135.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04436-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T15:48:47Z","timestamp":1673365727000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04436-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4436"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04436-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethical review board of the Scientific and Ethical Review Office of EPHI and Ethics Review Committee of the School of Pharmacy, Addis Ababa University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read the final manuscript and provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}